3-(3,4-dihydroxyphenyl)-2-hydroxy-propanoic acid

(Rac)-Salvianic acid A is the racemate of Salvianic acid A (HY-N1913). Salvianic acid A, an orally active phenolic compound, can induce Nrf2/HO-1 activation and inhibition of NF-κB pathway. Danshensu has anti-oxidation, anti-apoptosis, anti-lung inflammatory and has the potential for COVID-19, cardiovascular and cerebrovascular diseases research[1][2][3].

ChEBI: 3-(3,4-dihydroxyphenyl)lactic acid is a 2-hydroxy monocarboxylic acid and a member of catechols. It is functionally related to a rac-lactic acid. It is a conjugate acid of a 3-(3,4-dihydroxyphenyl)lactate.

[1] Wei Wang, et al. Danshensu alleviates pseudo-typed SARS-CoV-2 induced mouse acute lung inflammation. Acta Pharmacol Sin. 2022 Apr;43(4):771-780. DOI:10.1038/s41401-021-00714-4
[2] V Bharath Kumar, et al. Sodium Danshensu Inhibits Oral Cancer Cell Migration and Invasion by Modulating p38 Signaling Pathway. Front Endocrinol (Lausanne). 2020 Sep 30:11:568436. DOI:10.3389/fendo.2020.568436
[3] Chen Yu, et al. Danshensu attenuates cisplatin-induced nephrotoxicity through activation of Nrf2 pathway and inhibition of NF-κB. Biomed Pharmacother. 2021 Oct:142:111995. DOI:10.1016/j.biopha.2021.111995